Nicole Praschak-rieder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1252971/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World Journal of Biological Psychiatry, 2022, 23, 715-718.	2.6	6
2	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal of Affective Disorders Reports, 2021, 5, 100186.	1.7	3
3	Neuroimaging in Seasons and Winter Depression. , 2021, , 245-259.		0
4	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. NeuroImage, 2020, 223, 117270.	4.2	11
5	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry, 2020, 10, 2.	4.8	25
6	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. Journal of ECT, 2017, 33, e31-e32.	0.6	5
7	Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. European Journal of Neuroscience, 2017, 45, 45-57.	2.6	4
8	Making Sense of: Sensitization in Schizophrenia. International Journal of Neuropsychopharmacology, 2017, 20, 1-10.	2.1	44
9	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, 74-74.	2.1	1
10	In Vivo Imaging of Dopamine Metabolism and Dopamine Transporter Function in the Human Brain. Neuromethods, 2016, , 203-220.	0.3	3
11	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. Brain Structure and Function, 2016, 221, 103-114.	2.3	31
12	Reduced default mode network suppression during a working memory task in remitted major depression. Journal of Psychiatric Research, 2015, 64, 9-18.	3.1	99
13	Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. European Neuropsychopharmacology, 2015, 25, 2183-2184.	0.7	26
14	Direct Effect of Sunshine on Suicide. JAMA Psychiatry, 2014, 71, 1231.	11.0	117
15	Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans. Journal of Neuroscience, 2014, 34, 9917-9926.	3.6	59
16	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
17	Neuroimaging in Seasons and Winter Depression. , 2014, , 209-222.		0
18	ls Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence. Current Pharmaceutical Design, 2012, 18, 1568-1579.	1.9	24

#	Article	IF	CITATIONS
19	Effects of sunshine on suicide rates. Comprehensive Psychiatry, 2012, 53, 535-539.	3.1	60
20	Lichttherapie. , 2012, , 823-827.		0
21	Bright-Light Therapy in the Treatment of Mood Disorders. Neuropsychobiology, 2011, 64, 152-162.	1.9	205
22	Lithium in drinking water and suicide mortality. British Journal of Psychiatry, 2011, 198, 346-350.	2.8	142
23	Imaging of Seasonal Affective Disorder and Seasonality Effects on Serotonin and Dopamine Function in the Human Brain. Current Topics in Behavioral Neurosciences, 2011, 11, 149-167.	1.7	22
24	Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. NeuroImage, 2010, 53, 878-892.	4.2	82
25	Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention. Current Medical Research and Opinion, 2009, 25, 2281-2285.	1.9	3
26	Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. Journal of Psychiatric Research, 2009, 43, 792-797.	3.1	18
27	Seasonal Variation in Human Brain Serotonin Transporter Binding. Archives of General Psychiatry, 2008, 65, 1072.	12.3	224
28	Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder. Neuropsychopharmacology, 2008, 33, 1503-1513.	5.4	85
29	Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label Study. Pharmacopsychiatry, 2008, 41, 100-105.	3.3	24
30	Nichtpharmakologische somatische Therapien. , 2008, , 727-750.		0
31	Escitalopram in Seasonal Affective Disorder: Results of an Open Trial. Pharmacopsychiatry, 2007, 40, 20-24.	3.3	28
32	Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study. Biological Psychiatry, 2007, 62, 327-331.	1.3	186
33	Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology, 2007, 190, 575-579.	3.1	99
34	Serum lipid levels in seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 197-202.	3.2	7
35	Season of birth in siblings of patients with seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 378-382.	3.2	8
36	Anger attacks in seasonal affective disorder. International Journal of Neuropsychopharmacology, 2006, 9, 215.	2.1	12

NICOLE PRASCHAK-RIEDER

#	Article	IF	CITATIONS
37	Elevated Monoamine Oxidase A Levels in the Brain. Archives of General Psychiatry, 2006, 63, 1209.	12.3	507
38	A Cys23–Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian–Canadian collaborative study. Journal of Psychiatric Research, 2005, 39, 561-567.	3.1	8
39	Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy. Biological Psychiatry, 2005, 58, 331-336.	1.3	69
40	Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans. Biological Psychiatry, 2005, 58, 825-830.	1.3	92
41	Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. European Neuropsychopharmacology, 2004, 14, 53-58.	0.7	17
42	Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor–treated depression: An [18F] MPPF positron emission tomography study. Biological Psychiatry, 2004, 56, 587-591.	1.3	40
43	Seasonal affective disorder and the G-protein β-3-subunit C825T polymorphism. Biological Psychiatry, 2004, 55, 317-319.	1.3	26
44	Seasonality of Birth in Seasonal Affective Disorder. Journal of Clinical Psychiatry, 2004, 65, 1389-1393.	2.2	29
45	A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Molecular Psychiatry, 2003, 8, 942-946.	7.9	103
46	C825T polymorphism in the G protein β3-Subunit gene is associated with seasonal affective disorder. Biological Psychiatry, 2003, 54, 682-686.	1.3	38
47	Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference. Neuropsychopharmacology, 2003, 28, 734-739.	5.4	307
48	Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. International Journal of Neuropsychopharmacology, 2003, 6, 199-200.	2.1	1
49	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. Psychological Medicine, 2003, 33, 785-792.	4.5	37
50	Treatment of seasonal affective disorders. Dialogues in Clinical Neuroscience, 2003, 5, 389-398.	3.7	23
51	Association Between Serotonin Transporter Gene Promoter Polymorphism(5HTTLPR) and Behavioral Responses to Tryptophan Depletion in Healthy Women With and Without Family History of Depression. Archives of General Psychiatry, 2002, 59, 613.	12.3	193
52	Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology World Journal of Biological Psychiatry, 2002, 3, 133-146.	2.6	80
53	Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. European Neuropsychopharmacology, 2002, 12, 129-134.	0.7	38
54	Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 54-62.	3.2	33

#	Article	IF	CITATIONS
55	Reboxetine in seasonal affective disorder: an open trial. European Neuropsychopharmacology, 2001, 11, 1-5.	0.7	30
56	[123I] β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biological Psychiatry, 2001, 49, 326-332.	1.3	134
57	No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biological Psychiatry, 2001, 50, 8-12.	1.3	117
58	Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychological Medicine, 2001, 31, 1467-1473.	4.5	97
59	Monoaminergic function in the pathogenesis of seasonal affective disorder. International Journal of Neuropsychopharmacology, 2001, 4, 409-20.	2.1	63
60	Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. Journal of Affective Disorders, 2001, 63, 239-242.	4.1	50
61	Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2β-carbomethoxy-3β- (4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry, 2000, 47, 158-160.	1.3	70
62	[123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biological Psychiatry, 2000, 47, 482-489.	1.3	185
63	Mirtazapine in seasonal affective disorder (SAD): a preliminary report. Human Psychopharmacology, 1999, 14, 59-62.	1.5	21
64	Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene?. Psychiatry Research, 1999, 85, 241-246.	3.3	34
65	Monoamine Depletion in Non-Pharmacological Treatments for Depression. Advances in Experimental Medicine and Biology, 1999, 467, 29-33.	1.6	8
66	Light Treatment in Depression(SAD, s-SAD & non-SAD). , 1999, , 409-416.		5
67	Effects of Tryptophan Depletion in Drug-Free Depressed Patients Who Responded to Total Sleep Deprivation. Archives of General Psychiatry, 1998, 55, 167.	12.3	58
68	Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychological Medicine, 1998, 28, 257-264.	4.5	61
69	Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. American Journal of Psychiatry, 1997, 154, 1153-1155.	7.2	46
70	A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression. Drug Safety, 1997, 17, 251-264.	3.2	60
71	Suicidal Tendencies as a Complication of Light Therapy for Seasonal Affective Disorder. Journal of Clinical Psychiatry, 1997, 58, 389-392.	2.2	56
72	Severe Atypical Symptoms Without Depression in SAD. Journal of Clinical Psychiatry, 1997, 58, 495.	2.2	2